CEO Robert Barrow sells $721.7K of stock under 10b5-1 plan

What did Definium Therapeutics, Inc. announce?

CEO Robert Barrow sold 19,023 shares for a total value of $721,732.62, executed under a 10b5-1 trading plan.

Key details

• CEO Robert Barrow sold 19,023 shares.
• The total value of the transaction was $721,732.62.
• The sale was conducted under a 10b5-1 trading plan.

Why it matters

This 4 reports an insider transaction at Definium Therapeutics, Inc.. The likely share-price reaction reads as negative.